Conditions · Pancreatic cancer
Pancreatic cancer — Phase 1 trials
30 open options
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
RP-001
- TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Biospecimen Collection · Computed Tomography · Core Biopsy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
VB15010 — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Nogapendekin Alfa Inbakicept (N803) · Sotevtamab · Zabadinostat (CXD101)
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
CD318-CAR-T cells
- TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine · Nab paclitaxel · Erlotinib — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Carbon Nanoparticle-Loaded Iron [CNSI-Fe] · Carbon Nanoparticle-Loaded Iron — 9 sites
- TRIALPHASE1 / PHASE2RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Low-dose Radiotherapy · Pucotenlimab · AG regimen — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
[68Ga]Ga-DPI-4452 · [177Lu]Lu-DPI-4452 — 10 sites
- TRIALPHASE1 / PHASE2RECRUITING
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Directional Brachytherapy Source Implant — 6 sites
- TRIALPHASE1NOT_YET_RECRUITING
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
HSK41959 · Sintilimab · Pemetrexed + Cisplatin /Carboplatin — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
JAB-23E73 tablet，nab-paclitaxel，gemcitabine — 13 sites
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) · EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) · Lymphodepleting chemotherapy (Flu/Cy) — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — 18 sites
- TRIALPHASE1NOT_YET_RECRUITING
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
LT-010391 — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
TCR-T cells — 2 sites
- TRIALPHASE1RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in PDAC
iC9-CAR.B7-H3 T cell infusion — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
LUM015 · LUM 2.6 Imaging Device — 1 site
- TRIALPHASE1RECRUITING
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
Fecal Microbiota Transplantation · PEG3350 · Gemcitabine — 1 site
- TRIALPHASE1RECRUITING
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Samuraciclib · Computed Tomography · Endoscopic Ultrasound Biopsy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A 2-part Phase 1/2 Open-label Trial on ODM-212
ODM-212 · Ipilimumab and nivolumab · Gemcitabine and nab-paclitaxel — 2 sites
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
ASP2138 · Oxaliplatin · Leucovorin — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Evofosfamide · Zalifrelimab · Balstilimab — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BNT329 · CA19-9-targeting monoclonal antibody — 16 sites
- TRIALPHASE1RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
XL309 · Olaparib — 16 sites
- TRIALPHASE1RECRUITING
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
CL-NK-003 — 1 site
- TRIALPHASE1RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Metarrestin — 2 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.